

Raúl J Andrade

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3144786/publications.pdf>

Version: 2024-02-01

190
papers

13,652
citations

28274

55
h-index

23533

111
g-index

210
all docs

210
docs citations

210
times ranked

9373
citing authors

#	ARTICLE	IF	CITATIONS
1	Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e548-e563.	4.4	21
2	Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study. <i>Gastroenterology</i> Y <i>Hepatology</i> , 2022, 45, 342-349.	0.5	2
3	Safety of treating acute liver injury and failure. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 191-203.	2.4	6
4	Long-term sequelae of drug-induced liver injury. <i>Journal of Hepatology</i> , 2022, 76, 435-445.	3.7	21
5	A revised electronic version of RUCAM for the diagnosis of DILI. <i>Hepatology</i> , 2022, 76, 18-31.	7.3	52
6	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	3.7	21
7	Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency-associated hypertransaminasemia. <i>Hepatology</i> , 2022, 76, 1259-1274.	7.3	8
8	Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. <i>Biomedicines</i> , 2022, 10, 55.	3.2	4
9	Acute hepatitis with autoimmune features after COVID-19 vaccine: coincidence or vaccine-induced phenomenon?. <i>Gastroenterology Report</i> , 2022, 10, goac014.	1.3	15
10	Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen. <i>Antioxidants</i> , 2022, 11, 897.	5.1	3
11	N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2022, 13, .	3.5	18
12	Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. <i>Hepatology Communications</i> , 2022, 6, 1895-1909.	4.3	15
13	Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. <i>Pharmacological Research</i> , 2022, 182, 106348.	7.1	29
14	Profile of herbal and dietary supplements induced liver injury in Latin America: A systematic review of published reports. <i>Phytotherapy Research</i> , 2021, 35, 6-19.	5.8	13
15	Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1125-1135.	4.7	31
16	Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. <i>Drug Safety</i> , 2021, 44, 133-165.	3.2	19
17	Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1147-1158.	4.7	16
18	Genetic risk factors in the development of idiosyncratic drug-induced liver injury. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 153-169.	3.3	22

#	ARTICLE	IF	CITATIONS
19	Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. <i>Pharmacological Research</i> , 2021, 164, 105404.	7.1	29
20	Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. <i>Antioxidants</i> , 2021, 10, 390.	5.1	64
21	Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials. <i>Drug Safety</i> , 2021, 44, 619-634.	3.2	15
22	Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approach. <i>Archives of Toxicology</i> , 2021, 95, 1793-1803.	4.2	3
23	Serious liver injury induced by Nimesulide: an international collaborative study. <i>Archives of Toxicology</i> , 2021, 95, 1475-1487.	4.2	7
24	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4557.	4.1	34
25	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021, 41, 2076-2086.	3.9	13
26	Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan. <i>Liver International</i> , 2021, 41, 2671-2680.	3.9	9
27	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. <i>Journal of Hepatology</i> , 2021, 75, 86-97.	3.7	72
28	Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. <i>Journal of Hepatology</i> , 2021, 75, 333-341.	3.7	23
29	P041 Tandem mass tag-based quantitative proteomic profiling identifies novel putative serum biomarkers for the diagnosis of drug-induced liver injury in patients. , 2021, , .		1
30	Lymphocyte Profile and Immune Checkpoint Expression in Drug-Induced Liver Injury: An Immunophenotyping Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1604-1612.	4.7	15
31	Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. <i>Journal of Hepatology</i> , 2021, 75, 935-959.	3.7	66
32	Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. <i>Journal of Clinical Medicine</i> , 2021, 10, 5317.	2.4	3
33	Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3685-3726.	12.0	27
34	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41.	8.1	75
35	Development and Validation of Hepamet Fibrosis Scoring System – A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	4.4	104
36	Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. <i>Liver International</i> , 2020, 40, 6-17.	3.9	30

#	ARTICLE	IF	CITATIONS
37	Genetic Predisposition to Drug-Induced Liver Injury. <i>Clinics in Liver Disease</i> , 2020, 24, 11-23.	2.1	21
38	Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry. <i>Liver International</i> , 2020, 41, 1523-1531.	3.9	10
39	Drug induced liver injury: an update. <i>Archives of Toxicology</i> , 2020, 94, 3381-3407.	4.2	125
40	Drug-induced liver injury in older people. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 862-874.	8.1	42
41	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25.	3.7	59
42	Systematic review: ibuprofen-Induced liver injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 603-611.	3.7	32
43	Drug-Induced Liver Injury After Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1167-1176.	2.4	10
44	Protective role of c-Jun N-terminal kinase-2 (JNK2) in ibuprofen-Induced acute liver injury. <i>Journal of Pathology</i> , 2019, 247, 110-122.	4.5	8
45	Reply letter to "Editorial: bodybuilders beware". <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 473-473.	3.7	0
46	Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. <i>Gastroenterology</i> , 2019, 157, 552-568.	1.3	85
47	Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfectd with human immunodeficiency virus-1 in Spain. <i>PLoS ONE</i> , 2019, 14, e0225061.	2.5	4
48	Landscape of Liver Injury From Herbal and Dietary Supplements in Europe, Latin America, and Asia. <i>Clinical Liver Disease</i> , 2019, 14, 49-50.	2.1	2
49	Drug-induced liver injury. <i>Nature Reviews Disease Primers</i> , 2019, 5, 58.	30.5	409
50	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 245-253.	4.7	58
51	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1028-1036.	4.7	52
52	Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. <i>Gastroenterology</i> , 2019, 156, 2230-2241.e11.	1.3	346
53	Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. <i>Seminars in Liver Disease</i> , 2019, 39, 381-394.	3.6	20
54	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. <i>United European Gastroenterology Journal</i> , 2019, 7, 825-837.	3.8	29

#	ARTICLE	IF	CITATIONS
55	EASL Clinical Practice Guidelines: Drug-induced liver injury. <i>Journal of Hepatology</i> , 2019, 70, 1222-1261.	3.7	629
56	Next-Generation Sequencing of PTGS Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. <i>Frontiers in Genetics</i> , 2019, 10, 134.	2.3	10
57	When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American DILI Network (LATINDILIN). <i>Clinical Liver Disease</i> , 2019, 13, 51-57.	2.1	21
58	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019, 156, 1707-1716.e2.	1.3	97
59	Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. <i>Hepatology</i> , 2019, 69, 760-773.	7.3	166
60	Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. <i>Current Pharmaceutical Design</i> , 2019, 25, 3855-3871.	1.9	13
61	Herbal-induced liver injury: The price to pay for a healthier life?. <i>Liver International</i> , 2019, 39, 257-259.	3.9	0
62	Hepatic Damage by Natural Remedies. <i>Seminars in Liver Disease</i> , 2018, 38, 021-040.	3.6	33
63	Scientific opinion on the safety of green tea catechins. <i>EFSA Journal</i> , 2018, 16, e05239.	1.8	118
64	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502.	4.4	83
65	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , 2018, 68, 940-948.	3.7	15
66	Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 477-496.	0.2	2
67	High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 292-294.	4.4	18
68	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1260-1270.	3.7	70
69	The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury. <i>Liver International</i> , 2018, 39, 401-410.	3.9	10
70	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>Gastroenterology</i> , 2018, 155, 1120-1127.e4.	1.3	76
71	Chronic liver injury induced by drugs and toxins. <i>Journal of Digestive Diseases</i> , 2018, 19, 514-521.	1.5	30
72	Drug-induced liver injury: a safety review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 795-804.	2.4	31

#	ARTICLE	IF	CITATIONS
73	The pro-/anti-inflammatory effects of different fatty acids on visceral adipocytes are partially mediated by GPR120. <i>European Journal of Nutrition</i> , 2017, 56, 1743-1752.	3.9	35
74	A New Hepatoprotective Effect of Statins: Are They Always Safe for the Liver?. <i>American Journal of Gastroenterology</i> , 2017, 112, 384-385.	0.4	3
75	Drug-induced liver injury: recent advances in diagnosis and risk assessment. <i>Gut</i> , 2017, 66, 1154-1164.	12.1	370
76	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017, 152, 1078-1089.	1.3	174
77	Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. <i>Current Hepatology Reports</i> , 2017, 16, 286-292.	0.9	3
78	Drug-induced liver and skin reactions: In need of a consensus definition. <i>Hepatology</i> , 2017, 65, 391-391.	7.3	3
79	Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. <i>Liver International</i> , 2017, 37, 132-140.	3.9	25
80	Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. <i>PLoS ONE</i> , 2017, 12, e0189436.	2.5	13
81	A morphological method for ammonia detection in liver. <i>PLoS ONE</i> , 2017, 12, e0173914.	2.5	28
82	Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. <i>International Journal of Molecular Sciences</i> , 2016, 17, 537.	4.1	114
83	The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. <i>International Journal of Molecular Sciences</i> , 2016, 17, 313.	4.1	63
84	Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. <i>International Journal of Molecular Sciences</i> , 2016, 17, 714.	4.1	69
85	Drug, Herb, and Dietary Supplement Hepatotoxicity. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1488.	4.1	24
86	Biomarkers in DILI: One More Step Forward. <i>Frontiers in Pharmacology</i> , 2016, 7, 267.	3.5	52
87	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients. <i>Frontiers in Pharmacology</i> , 2016, 7, 280.	3.5	3
88	Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 414-422.	1.5	21
89	Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1611-1618.	2.8	25
90	Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases. <i>Liver International</i> , 2016, 36, 302-310.	3.9	39

#	ARTICLE	IF	CITATIONS
91	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <i>Journal of Hepatology</i> , 2016, 65, 532-542.	3.7	115
92	Characterizing Drug-Induced Liver Injury With Autoimmune Features. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1844-1845.	4.4	8
93	Hepatotoxicity induced by coxibs: how concerned should we be?. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1463-1475.	2.4	26
94	Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions. <i>Drug Safety</i> , 2016, 39, 925-943.	3.2	30
95	Creating an effective clinical registry for rare diseases. <i>United European Gastroenterology Journal</i> , 2016, 4, 333-338.	3.8	31
96	“Drug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challenge” <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 589-593.	3.3	17
97	Reply. <i>Gastroenterology</i> , 2015, 148, 452-453.	1.3	0
98	Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity?. <i>Journal of Hepatology</i> , 2015, 62, 751-752.	3.7	31
99	Reducing Risk of Severe Liver Injury in Patients Treated With Isoniazid. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1683-1685.	4.4	4
100	Drug-induced liver injury: Interactions between drug properties and host factors. <i>Journal of Hepatology</i> , 2015, 63, 503-514.	3.7	319
101	The value of serum aspartate aminotransferase and gamma-glutamyl transpeptidase as biomarkers in hepatotoxicity. <i>Liver International</i> , 2015, 35, 2474-2482.	3.9	47
102	Drug-Induced Liver Injury: Expanding Our Knowledge by Enlarging Population Analysis With Prospective and Scoring Causality Assessment. <i>Gastroenterology</i> , 2015, 148, 1271-1273.	1.3	33
103	Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <i>Annals of Hepatology</i> , 2014, 13, 231-239.	1.5	27
104	Drug-Induced Liver Injury Due to Antimicrobials, Central Nervous System Agents, and Nonsteroidal Anti-Inflammatory Drugs. <i>Seminars in Liver Disease</i> , 2014, 34, 145-161.	3.6	31
105	Reply. <i>Gastroenterology</i> , 2014, 147, 1442.	1.3	0
106	Liver Safety Assessment: Required Data Elements and Best Practices for Data Collection and Standardization in Clinical Trials. <i>Drug Safety</i> , 2014, 37, 19-31.	3.2	32
107	Mechanisms of drug-induced liver injury. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014, 14, 286-292.	2.3	86
108	Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2014, 147, 109-118.e5.	1.3	248

#	ARTICLE	IF	CITATIONS
109	Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort. PLoS ONE, 2014, 9, e94675.	2.5	19
110	Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World Journal of Hepatology, 2014, 6, 160.	2.0	105
111	Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. Annals of Hepatology, 2014, 13, 231-9.	1.5	9
112	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. Annals of Hepatology, 2014, 13, 356-63.	1.5	12
113	Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury. Liver International, 2013, 33, 1378-1385.	3.9	38
114	Causality Assessment. , 2013, , 287-302.		1
115	HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity. PLoS ONE, 2013, 8, e68111.	2.5	81
116	Metformin-Induced Hepatotoxicity. Diabetes Care, 2012, 35, e21-e21.	8.6	45
117	Plasma Ribavirin Trough Concentrations During Treatment of Chronic Hepatitis C in Genotype-1 Patients. Journal of Clinical Gastroenterology, 2012, 46, 328-333.	2.2	5
118	Trends in Qualifying Biomarkers in Drug Safety. Consensus of the 2011 Meeting of the Spanish Society of Clinical Pharmacology. Frontiers in Pharmacology, 2012, 3, 2.	3.5	11
119	Genetic variations in drug-induced liver injury (DILI): resolving the puzzle. Frontiers in Genetics, 2012, 3, 253.	2.3	12
120	Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis. Revista Espanola De Enfermedades Digestivas, 2012, 104, 282-283.	0.3	9
121	Building a Spanish-Latin American network on drug induced liver injury: much to get from a joint collaborative initiative. Annals of Hepatology, 2012, 11, 544-9.	1.5	9
122	Hepatic safety of antibiotics used in primary care. Journal of Antimicrobial Chemotherapy, 2011, 66, 1431-1446.	3.0	154
123	Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 817-828.	3.3	48
124	Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. Gastroenterology, 2011, 141, 338-347.	1.3	412
125	Causality assessment methods in drug induced liver injury: Strengths and weaknesses. Journal of Hepatology, 2011, 55, 683-691.	3.7	164
126	Drug-Induced Autoimmune-Like Hepatitis: A Diagnostic Challenge. Digestive Diseases and Sciences, 2011, 56, 2501-2503.	2.3	16

#	ARTICLE	IF	CITATIONS
127	Continuous reporting of new cases in Spain supports the relationship between Herbalife® products and liver injury. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1080-1087.	1.9	34
128	The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. <i>Hepatology</i> , 2011, 54, 931-939.	7.3	279
129	Sertraline Hepatotoxicity: Report of a Case and Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1806-1807.	2.3	23
130	Metformin improves sustained virologic response in difficult-to-cure hepatitis C: More questions than answers. <i>Hepatology</i> , 2010, 51, NA-NA.	7.3	0
131	Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2010, 52, 303-312.	7.3	97
132	Antibiotic-Induced Liver Toxicity: Mechanisms, Clinical Features and Causality Assessment. <i>Current Drug Safety</i> , 2010, 5, 212-222.	0.6	34
133	Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in Vigibase®, <i>Drug Safety</i> , 2010, 33, 503-522.	3.2	142
134	S1873 The use of Liver Biopsy Evaluation in Determination of Autoimmune Hepatitis vs. Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2010, 138, S-807.	1.3	1
135	Rechallenge in drug-induced liver injury: the attractive hazard. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 709-714.	2.4	47
136	Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute <i>Mycoplasma pneumoniae</i> infection. <i>Clinical Therapeutics</i> , 2009, 31, 1014-1019.	2.5	26
137	Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. <i>Hepatology</i> , 2009, 49, 2001-2009.	7.3	266
138	Reply:. <i>Hepatology</i> , 2009, 49, 1777-1779.	7.3	0
139	Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. <i>Hepatology</i> , 2009, 50, 1702-1708.	7.3	136
140	Corrigendum to “Analysis of IL-10, IL-4 and TNF- α polymorphisms in drug-induced liver injury (DILI) and its outcome” [J Hepatol 49 (2008) 107-114]. <i>Journal of Hepatology</i> , 2009, 50, 636.	3.7	1
141	Drug-induced liver injury: insights from genetic studies. <i>Pharmacogenomics</i> , 2009, 10, 1467-1487.	1.3	90
142	Pharmacogenomics in Drug Induced Liver Injury. <i>Current Drug Metabolism</i> , 2009, 10, 956-970.	1.2	70
143	Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. <i>Hepatology</i> , 2008, 47, 810-816.	7.3	51
144	Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2008, 48, 588-596.	7.3	181

#	ARTICLE	IF	CITATIONS
145	Assessment of drug-induced liver injury in clinical practice. <i>Fundamental and Clinical Pharmacology</i> , 2008, 22, 141-158.	1.9	66
146	Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. <i>Journal of Hepatology</i> , 2008, 48, 721-727.	3.7	175
147	Analysis of IL-10, IL-4 and TNF- α polymorphisms in drug-induced liver injury (DILI) and its outcome. <i>Journal of Hepatology</i> , 2008, 49, 107-114.	3.7	72
148	Idiosyncratic drug hepatotoxicity: a 2008 update. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 261-276.	3.1	18
149	Statins: Hepatic Disease and Hepatotoxicity Risk. <i>The Open Gastroenterology Journal</i> , 2008, 2, 18-23.	0.1	4
150	Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review. <i>Current Drug Safety</i> , 2007, 2, 97-112.	0.6	26
151	Assessment of drug-induced hepatotoxicity in clinical practice: A challenge for gastroenterologists. <i>World Journal of Gastroenterology</i> , 2007, 13, 329.	3.3	134
152	Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment. <i>Gastroenterology</i> , 2006, 131, 451-460.	1.3	361
153	Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain. <i>Hepatology</i> , 2006, 44, 850-856.	7.3	143
154	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. <i>Hepatology</i> , 2006, 44, 1581-1588.	7.3	267
155	Incidence of and Factors Associated with Hepatocellular Carcinoma among Hepatitis C Virus and Human Immunodeficiency Virus Coinfected Patients with Decompensated Cirrhosis. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 1236-1241.	1.1	17
156	Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: Is there still a role for these drugs. <i>World Journal of Gastroenterology</i> , 2006, 12, 5078.	3.3	14
157	Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. <i>World Journal of Gastroenterology</i> , 2006, 12, 5244-6.	3.3	18
158	Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels. <i>Antiviral Therapy</i> , 2006, 11, 491-8.	1.0	3
159	The administration of N-acetylcysteine causes a decrease in prothrombin time in patients with paracetamol overdose but without evidence of liver impairment. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 59-63.	1.6	16
160	HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology</i> , 2005, 41, 779-789.	7.3	245
161	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <i>Gastroenterology</i> , 2005, 129, 512-521.	1.3	847
162	HLA-C and KIR Genes in Hepatitis C Virus Infection. <i>Human Immunology</i> , 2005, 66, 1106-1109.	2.4	41

#	ARTICLE	IF	CITATIONS
163	Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. <i>Gastroenterology</i> , 2005, 128, 636-641.	1.3	699
164	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <i>Gastroenterology</i> , 2005, 129, 512-521.	1.3	595
165	Is the Naranjo Probability Scale Accurate Enough to Ascertain Causality in Drug-Induced Hepatotoxicity?. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1540-1541.	1.9	19
166	Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis. <i>American Journal of Gastroenterology</i> , 2004, 99, 2150-2157.	0.4	21
167	HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. <i>Hepatology</i> , 2004, 39, 1603-1612.	7.3	134
168	Causality assessment in drug-induced hepatotoxicity. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 329-344.	2.4	70
169	Drug use for non-hepatic associated conditions in patients with liver cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 71-76.	1.9	30
170	Acute leukemia after infliximab therapy. <i>American Journal of Gastroenterology</i> , 2003, 98, 2577.	0.4	7
171	Antidepressant-induced hepatotoxicity. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 249-262.	2.4	75
172	Lansoprazole-Induced Hepatic Dysfunction. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1731-1731.	1.9	6
173	Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 887-890.	1.6	45
174	Chronic Hepatitis C, Ibuprofen, and Liver Damage. <i>American Journal of Gastroenterology</i> , 2002, 97, 1854-1855.	0.4	19
175	Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 435-440.	1.9	72
176	Unusual duodenal duplication cyst associated with partial gastric diverticulum in a middle-aged woman: are they congenital or acquired?. <i>Digestive Diseases and Sciences</i> , 2002, 47, 304-308.	2.3	3
177	Acute Fulminant Hepatitis After Treatment With Rabeprazole and Terbinafine: Is Rabeprazole the Culprit?. <i>Archives of Internal Medicine</i> , 2002, 162, 360-361.	3.8	9
178	Hepatotoxicity in patients with cirrhosis, an often unrecognized problem: lessons from a fatal case related to amoxicillin/clavulanic acid. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1416-1419.	2.3	15
179	Comparison of two clinical scales for causality assessment in hepatotoxicity. <i>Hepatology</i> , 2001, 33, 123-130.	7.3	240
180	Benzylpenicillin-Induced Prolonged Cholestasis. <i>Annals of Pharmacotherapy</i> , 2001, 35, 783-784.	1.9	25

#	ARTICLE	IF	CITATIONS
181	Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 929-935.	3.7	19
182	Portal hypertension and refractory ascites associated with multicentric Castleman's disease. <i>Digestive Diseases and Sciences</i> , 2000, 45, 697-702.	2.3	3
183	Trovafloxacin-Induced Acute Hepatitis. <i>Clinical Infectious Diseases</i> , 2000, 30, 400-401.	5.8	91
184	Letters to the Editor. <i>Journal of Hepatology</i> , 2000, 32, 174.	3.7	33
185	Acute liver failure after treatment with nefazodone. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2577-2579.	2.3	38
186	Acute liver injury associated with the use of ebrotidine, a new H ₂ -receptor antagonist. <i>Journal of Hepatology</i> , 1999, 31, 641-646.	3.7	55
187	Severe idiosyncratic acute hepatic injury caused by paracetamol. <i>Journal of Hepatology</i> , 1998, 28, 1078.	3.7	17
188	Norfloxacin-Induced Cholestatic Jaundice. <i>American Journal of Gastroenterology</i> , 1998, 93, 2309-2311.	0.4	20
189	Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. <i>Journal of Hepatology</i> , 1995, 22, 189-196.	3.7	32
190	Apolipoprotein distribution in plasma HDL subfractions in alcohol consumers. <i>Drug and Alcohol Dependence</i> , 1990, 26, 161-168.	3.2	5